Iovance Biotherapeutics IOVA
United StatesHealthcare · BiotechnologyUSD
12.80 USD (−0.9%)
10 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Iovance Biotherapeutics is a biotechnology company developing personalized cell therapies (tumor-infiltrating lymphocytes, TIL) for advanced cancers, with its first FDA-approved product.
Key points
from its scores- ✓Strong growth10.0
- ✓Good share-price trend9.8
- ✕Demanding valuation0.8
- ✕Little or no dividend1.5
- ✕Little competitive advantage2.5
AI analysis
bottom line, main risk, context and newsGrowth potential is high but execution risk and lack of profitability warrant caution.
Iovance shows exceptional revenue growth (65.7%) and strong momentum (309.5% in 12 months), but is not yet profitable (operating margin -52.3%) and its valuation is demanding (FCF yield -3.2%), reflecting high expectations for its cell therapy pipeline.
The main risk is dependence on regulatory approvals and commercial success of its cell therapies, along with cash burn until reaching profitability.
Context and risks
Iovance operates in the highly FDA-regulated cell therapy sector. Although no known litigation exists, approval and commercialization of its products depend on the agency, and any regulatory change or delay in clinical trials could materially affect future revenues. Additionally, the company is not yet profitable, increasing sensitivity to adverse regulatory conditions.
Is Iovance Biotherapeutics stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 427% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 7.9 | 4.1 | +93% |
| Price / sales | 18.0 | 3.4 | +427% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 12.80 USD, −0.9% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 2.5 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −54.5
- EV / EBITDA
- −21.6
- Price / book
- 7.9
- Price / sales
- 18.0
- Market cap
- 5.9B USD
- Enterprise value
- 5.6B USD
Profitability
- ROE
- −40.4%
- ROA
- −20.3%
- ROIC (approx.)
- −21.7%
- Gross margin
- 48.4%
- Operating margin
- −52.3%
- Net margin
- −89.1%
- Free cash flow
- −187.8M USD
- FCF yield
- −3.2%
Solvency
- Total debt
- 46.0M USD
- Net debt
- −251.7M USD
- Cash
- 297.7M USD
- EBITDA
- −259.6M USD
- Net debt / EBITDA
- 0.97
- Debt / equity
- 6.25
- Current ratio
- 4.34
- Quick ratio
- 3.74
Growth
- Revenue growth
- +65.7%
- EPS (TTM)
- −0.69 USD
- EPS (forward)
- −0.24 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.76
- Analyst consensus
- Buy (10)
- Target price
- 12.80 USD
- 52-week range
- 1.76 – 15.30
Recent news
All IOVA news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Iovance Biotherapeutics
Is Iovance Biotherapeutics stock cheap or expensive?
On Price / sales, it trades 427% above the Healthcare median. Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 12.80 USD, −0.9% versus the price. This is not investment advice.
What score does Iovance Biotherapeutics get on MeridIAn Screener?
It scores 4.7 out of 10, rank 1,816 of 2,130 (better than 14% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Valuation (0.8). Analysis of 08/10/2026.
How much is Iovance Biotherapeutics worth on the stock market?
Its market capitalisation is 5.9B USD and its enterprise value, debt included, is 5.6B USD.
How much debt does Iovance Biotherapeutics have?
It has more cash than debt: net cash of 251.7M USD.
Does Iovance Biotherapeutics pay a dividend?
It pays no dividend, or almost none.
How has Iovance Biotherapeutics stock performed over the last year?
It has risen 514.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 1.76 and 15.30 USD. Past performance does not guarantee future results.
What do analysts think of Iovance Biotherapeutics?
10 analysts cover it; their average recommendation is “Buy” and their average target is 12.80 USD (−0.9% versus the price). It is an estimate, not market data.